|Year : 2011 | Volume
| Issue : 2 | Page : 177-180
Clinical evaluation of Vardhamana Pippali Rasayana in the management of Amavata (Rheumatoid Arthritis)
Anamika Soni1, Kalapi Patel2, SN Gupta3
1 Lecturer, Department of Kaya Chikitsa, JS Ayurveda College, Nadiad, India
2 Reader and Head, Department of Panchakarma, JS Ayurveda College, Nadiad, India
3 Professor and Head, Department of Kaya Chikitsa, JS Ayurveda College, Nadiad, Gujarat, India
|Date of Web Publication||2-Feb-2012|
Doctors' Staff Quarters, JS Ayurved Mahavidyalaya, College Road, Nadiad 387 001
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Amavata is described as a difficult to cure (Krichhrasadhya) disease in Ayurveda. Pain in joints with swelling is a cardinal feature of this disease. It can be correlated with rheumatoid arthritis described in modern medical science. In conventional medical science, steroids and some nonsteroidal anti-inflammatory drugs are used for its management, but they cause certain dangerous side effects in the patients. Ayurveda promises an excellent therapy for it. The present clinical trial was conducted with the same objective to provide a safe, economical and effective therapy to the patients of Amavata. The present study was conducted in 73 patients having classical symptoms of Amavata. The patients were given Vardhamana Pippali Rasayana for 15 days. Patients with any other acute or chronic systemic illness or infection were excluded from the study. The observations and results obtained were analyzed statistically applying the "t" test. All the patients experienced up to 50% relief from the signs and symptoms of Amavata after the therapy. The drug might have produced its beneficial effects in the patients of Amavata due to its Agnideepana, Amapachana, Vatashamaka and Rasayana effects in the body. A significant decrease in the erythrocyte sedimentation rate in all the patients was also noticed. All the results obtained were highly significant statistically. Thus, it can be implicated that the Vardhamana Pippali Rasayana has a lot of beneficial effects in the patients of Amavata.
Keywords: Amavata , Rasayana, Rheumatoid arthritis, Vardhamana Pippali
|How to cite this article:|
Soni A, Patel K, Gupta S N. Clinical evaluation of Vardhamana Pippali Rasayana in the management of Amavata (Rheumatoid Arthritis). AYU 2011;32:177-80
|How to cite this URL:|
Soni A, Patel K, Gupta S N. Clinical evaluation of Vardhamana Pippali Rasayana in the management of Amavata (Rheumatoid Arthritis). AYU [serial online] 2011 [cited 2020 Jul 15];32:177-80. Available from: http://www.ayujournal.org/text.asp?2011/32/2/177/92555
| Introduction|| |
Amavata is one of the most difficult to cure (Krichhrasadhya) diseases mentioned in Ayurveda. The main pathological factor in the development of this disease is "Ama". Ama is a substance which is produced in the body due to weakness of agni. This Ama is then carried by "Vata" and travels throughout the body and gets accumulated in the joints, which is the seat of "Kapha". As this process continuous, all the joints are gradually affected, which results in severe pain and swelling in the joints.  When "Pitta" also gets associated, it causes burning sensation around the joints. Clinically, it is very much close to rheumatoid arthritis described in modern medical science, which is a chronic inflammatory autoimmune disease involving multiple joints of the body. In modern medicine, the treatment of the disease includes steroids and immunomodulator drugs together with nonsteroidal anti-inflammatory drugs (NSAIDs).  Long-term use of these drugs has many adverse effects on the other systems of the body. But the use of Ayurvedic drugs having Dipana, Pachana, Srotoshodhana and Rasayana actions like Pippali (Piper longum) can be beneficial to these patients. Further, it is free from the serious adverse effects as compared to the modern conventional therapy, provided it is given in proper dose and regimen.
Pippali has Dipana, Pachana and Rasayana actions  and is helpful in alleviating Ama from the body which is the basic pathological factor in this disease, i.e. rheumatoid arthritis. It is one of the Rasayana drugs described in Charaka samhita. The use of Pippali in gradually increasing and tapering dose known as Vardhamana Pippali is more effective because it can be administered in its maximum doses without any discomfort to the patient. The present clinical study was carried out in 73 clinically diagnosed cases of Amavata (rheumatoid arthritis) to evaluate the role of Vardhamana Pippali Rasayana in Amavata.
Aims and objectives
- To evaluate the efficacy of Vardhamana Pippali in patients of Amavata (rheumatoid arthritis)
- To provide a safe, economical and effective remedy to the patients of Amavata
| Materials and Methods|| |
The clinical study was carried out in 73 clinically diagnosed patients of Amavata registered in IPD of JS Ayurvedic College and PD Patel Ayurvedic Hospital, Nadiad.
The criteria of inclusion of patients were based on the signs and symptoms of Amavata (rheumatoid arthritis). They are
The patients were selected randomly irrespective of their age, sex, religion, etc.
- morning stiffness (>1 hour);
- arthritis of three or more joints and
- symmetrical arthritis.
The patients having any other chronic systemic illness, metabolic diseases like gout, with severe deformities and endocrinological diseases were excluded from the study.
Criteria for assessment
All the symptoms were given score to assess the effect of the treatment objectively. Erythrocyte sedimentation rate (ESR) was recorded before and after the treatment. The scoring pattern is as given in [Table 1].
Criteria for assessment of the effect of Vardhamana Pippali Rasayana on symptoms of Amavata
Unchanged: Less than 25% relief in symptoms
Improved: 25-49% relief in symptoms
Markedly improved: 50-99% relief in symptoms
Complete remission: 100% relief in symptoms
Administration of the drug
Drug: Pippali Churna (powder of P. longum)
Powder of Pippali (P. longum) in Vardhamana Krama, i.e. starting the dose from 1 g on the first day, twice a day with honey, was given . It was increased by 1 g daily up to a maximum dose of 5 g twice a day. The maximum dose, i.e. 5 g, was given for 5 days and then it was tapered by 1 g daily to a dose of 1 g twice a day. Patients were kept on Mudga yusha. Total duration of the treatment was 15 days. All the patients were given Mridu Virechana with Eranda taila (Castor oil) in doses of 30-40 ml with hot water according to their Koshtha and the strength on next day after the completion of the Vardhamana Pippali regimen. Any change in symptoms and ESR was recorded after the completion of regimen.
| Results and Observations|| |
[Table 2], [Table 3], [Table 4], [Table 5] and [Table 6] show the results and observations of the study. Total 43 patients (58.9%) were in the age group of 41-60 years, followed by 24 patients (32.8%) in the age group of 21-40 years. 4 patients (5.47%) were aged more than 60 years and only 2 patients (2.73%) were less than 20 years of age [Table 2]. Total 57 (78.08%) patients were females, whereas 16 (21.90%) patients were males [Table 3]. Maximum, i.e. 41% patients, were suffering from the disease for less than 1 year, 38.35% patients were having duration of illness 1-3 years and 20.54% patients were having symptoms of the disease for more than 1 year [Table 4].Improvement in the symptom of pain in joints was 50.56% which is statistically highly significant. Stiffness in the joints decreased by 48.57% which is statistically highly significant.
|Table 4: Chronicity wise distribution of 73 registered patients of Amavata|
Click here to view
|Table 5: Effect of Vardhamana Pippali Rasayana on the symptoms of Amavata in 73 registered patients of Amavata|
Click here to view
|Table 6: Effect of Vardhamana Pippali Rasayana on ESR in 73 registered patients of Amavata|
Click here to view
Swelling in the joints also decreased by 53.22% which is also statistically highly significant. The improvement in the symptom of restriction in the movements in the joints was 46.43% which is statistically highly significant [Table 5]. A significant decrease in ESR (17.67%) was observed in the patients registered for the study after the completion of treatment course, which is statistically highly significant[Table 6].
During the course of the treatment, none of the patients showed any adverse reactions.
| Discussion|| |
The basic pathology in the Amavata is the formation of Ama in the body due to Agnimandya,  followed by vitiation of all the three doshas, predominantly Vata. Rheumatoid arthritis is an autoimmune disorder and it can be equated with Amavata. Balabhramsha is described as one of the clinical consequences of Ama. Balabhrmasha may be interpreted as Ayathaprarvrtti of Bala. Bala is very well accepted as an immune component by Ayurvedic scholars. Hence, Balabhrmasha or Ayathaprarvrtti of Bala can be understood as altered immune activity or autoimmune disorders. The use of Pippali in increasing and tapering doses is known as "Vardhamana Pippali". It is very effective because it can be administered in its maximum doses without any discomfort to the patient. Of all the 73 patients registered for the present study, 43 patients (58.9%) were in the age group of 21-40 years and most of them (78%) were females. Most of the patients were having duration of illness 1-3 years. The use of Vardhamana Pippali Rasayana in 73 registered cases of Amavata caused 50.56% relief from the symptom of pain in joints, 48.7% relief from the symptom of stiffness in the joints, 53.25% relief from the swelling in joints and 46.20% relief from restriction of movements. All these results were found to be statistically highly significant (P < 00.001). A remarkable reduction (17.76%) in ESR was also noticed in the patients registered for the current clinical study and this result is also statistically highly significant (P < 0.001). Further, no specific side/adverse effects were noticed in any of the patients registered for the present clinical trial.
Pippali is one of the Rasayana drugs described in Ayurveda. It has Agnidipana and Amapachana actions and is helpful in the alleviation of Ama from the body which is the main pathological factor in Amavata, i.e. rheumatoid arthritis. Pippali alleviates Ama, the factor responsible for Balabhrmsha or development of autoimmune disorders in the body, resulting in the correction in immune system activities. Pippali has rasayana and immunomodulator actions. Thus, because of all these actions together, it plays an important role in the Samprapti-vighatana of the Amavata, i.e. rhematoid arthritis. Further, the drug is very much economical and the therapy is very cost-effective also.
| Conclusion|| |
On the basis of observations and discussion of this study, the following conclusions can be drawn.
- Vardhamana Pippali Rasayana has a lot of beneficial effects in the patients of Amavata.
- It is free from any side effects.
- It is also very much cost-effective.
| Acknowledgment|| |
Authors are thankful to the management and the principal of JS Ayurvedic College and PD Patel Ayurved Hospital for providing the permission and facilities for conducting the present trial.
| References|| |
|1.||Agnivesha, Charaka, Dridhbala, Charaka Samhita, Grahanichikitsa Adhyaya , Shloka no. 42-44, Vidyotini Hindi commentary, translated by Pt. Shastri Kashinatha and Chaturvedi G.N., 14 th ed. Varanasi: Chaukhamba Bharti Academy; 1987. p. 460. |
|2.||Madhavakara, Madhava Nidana, Vol. 2, Amvatanidanam Adhyaya, Shloka no. 1-5, Vidyotini Hindi commentary by Shastri Sudarshana. 20 th ed. Varanasi: Chaukhamba Sanskrit Samsthana; 1992. p. 498. |
|3.||Haslet C, Chilvers ER, Hunter JR, Nicholos A., Davidson's Principles and Practice of Medicine. 18 th ed. New Delhi: Churchill Livingstone Publication; 2000. p. 898. |
|4.||Dwivedi Vishwanatha Bhava Prakasha Nighantu. 9 th ed. New Delhi: Motilal Banarsidas press; 1998. p. 14. |
|5.||Agnivesha, Charaka, Dridhbala, Charaka Samhita, Rasayana Adhyaya- Pada-3, Shloka no. 436-40, Vidyotini Hindi commentary, translated by Pt. Shastri Kashinatha and Chaturvedi G.N., 14 th ed. Varanasi: Chaukhamba Bharti Academy; 1987. p. 39. |
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6]